{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T15:49:36Z","timestamp":1781279376926,"version":"3.54.1"},"reference-count":132,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T00:00:00Z","timestamp":1646956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoF"],"abstract":"<jats:p>Mushrooms have been used as traditional medicine for millennia, fungi are the main natural source of psychedelic compounds. There is now increasing interest in using fungal active compounds such as psychedelics for alleviating symptoms of mental health disorders including major depressive disorder, anxiety, and addiction. The anxiolytic, antidepressant and anti-addictive effect of these compounds has raised awareness stimulating neuropharmacological investigations. Micro-dosing or acute dosing with psychedelics including Lysergic acid diethylamide (LSD) and psilocybin may offer patients treatment options which are unmet by current therapeutic options. Studies suggest that either dosing regimen produces a rapid and long-lasting effect on the patient post administration with a good safety profile. Psychedelics can also modulate immune systems including pro-inflammatory cytokines suggesting a potential in the treatment of auto-immune and other chronic pain conditions. This literature review aims to explore recent evidence relating to the application of fungal bioactives in treating chronic mental health and chronic pain morbidities.<\/jats:p>","DOI":"10.3390\/jof8030290","type":"journal-article","created":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T12:58:36Z","timestamp":1647003516000},"page":"290","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Mycotherapy: Potential of Fungal Bioactives for the Treatment of Mental Health Disorders and Morbidities of Chronic Pain"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3867-9712","authenticated-orcid":false,"given":"Elaine","family":"Meade","sequence":"first","affiliation":[{"name":"Department of Life Science, Sligo Institute of Technology, F91 YW50 Sligo, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Hehir","sequence":"additional","affiliation":[{"name":"Department of Life Science, Sligo Institute of Technology, F91 YW50 Sligo, Ireland"},{"name":"Centre for Precision Engineering, Materials and Manufacturing Research (PEM), Institute of Technology, F91 YW50 Sligo, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Rowan","sequence":"additional","affiliation":[{"name":"Bioscience Research Institute, Technical University Shannon Midlands Midwest, N37 HD68 Athlone, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1240-5315","authenticated-orcid":false,"given":"Mary","family":"Garvey","sequence":"additional","affiliation":[{"name":"Department of Life Science, Sligo Institute of Technology, F91 YW50 Sligo, Ireland"},{"name":"Centre for Precision Engineering, Materials and Manufacturing Research (PEM), Institute of Technology, F91 YW50 Sligo, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association (2013). DSM 5 Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Association.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/NMD.0b013e318288e23f","article-title":"Stigmatizing attitudes differ across mental health disorders: A comparison of stigma across eating disorders, obesity, and major depressive disorder","volume":"201","author":"Ebneter","year":"2013","journal-title":"J. Nerv. Ment. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/496416a","article-title":"Mental health: On the spectrum","volume":"496","author":"Adam","year":"2013","journal-title":"Nature"},{"key":"ref_4","first-page":"168","article-title":"Lifetime prevalence and age-of-onset distributions of mental disorders in the World Health Organization\u2019s World Mental Health Survey Initiative","volume":"6","author":"Kessler","year":"2007","journal-title":"World Psychiatry"},{"key":"ref_5","unstructured":"World Health Organisation (2022, February 23). Mental Health. Available online: https:\/\/www.who.int\/health-topics\/mental-health#tab=tab_12021."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.15252\/embr.201642951","article-title":"The economic costs of mental disorders: Do our societies react appropriately to the burden of mental disorders?","volume":"17","author":"Trautmann","year":"2016","journal-title":"EMBO Rep."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Chong, P.S., Fung, M.-L., Wong, K.H., and Lim, L.W. (2019). Therapeutic Potential of Hericium erinaceus for Depressive Disorder. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21010163"},{"key":"ref_8","first-page":"5","article-title":"Issues in treatment-resistant depression","volume":"66","author":"Keller","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"ref_9","first-page":"369","article-title":"Treatment-resistant depression: Therapeutic trends, challenges, and future directions","volume":"6","year":"2012","journal-title":"Patient Prefer. Adherence"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1177\/0269881114568039","article-title":"Psychedelics not linked to mental health problems or suicidal behavior: A population study","volume":"29","author":"Johansen","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"ref_11","first-page":"1","article-title":"Attitudes and Beliefs about the Therapeutic Use of Psychedelic Drugs among Psychologists in the United States","volume":"53","author":"Davis","year":"2021","journal-title":"J. Psychoact. Drugs"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1080\/14656566.2018.1491966","article-title":"Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: An evidence-based treatment review","volume":"19","author":"Strawn","year":"2018","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.3389\/fpsyt.2020.595584","article-title":"Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. Review","volume":"11","author":"Garakani","year":"2020","journal-title":"Front. Psychiatry"},{"key":"ref_14","unstructured":"Moraczewski, J., and Aedma, K.K. (2022). Tricyclic Antidepressants, StatPearls Publishing."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3949\/ccjm.86a.19005","article-title":"Beyond depression: Other uses for tricyclic antidepressants","volume":"86","author":"Schneider","year":"2019","journal-title":"Clevel. Clin. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s40263-021-00832-x","article-title":"Monoamine oxidase inhibitors (MAOIs) in psychiatric practice: How to use them safely and effectively","volume":"35","author":"Chamberlain","year":"2021","journal-title":"CNS Drugs"},{"key":"ref_17","unstructured":"Sub Laban, T., and Saadabadi, A. (2022). Monoamine Oxidase Inhibitors (MAOI), StatPearls Publishing."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"326","DOI":"10.9740\/mhc.2020.11.326","article-title":"Management of treatment-resistant generalized anxiety disorder","volume":"10","author":"Ansara","year":"2020","journal-title":"Ment. Health Clin."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"107402","DOI":"10.1016\/j.pharmthera.2019.107402","article-title":"Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders","volume":"204","author":"Sartori","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"ref_20","first-page":"20","article-title":"Buspirone: A forgotten friend","volume":"19","author":"Shmuts","year":"2020","journal-title":"Curr. Psychiatry"},{"key":"ref_21","unstructured":"Wilson, T.K., and Tripp, J. (2022). Buspirone, StatPearls Publishing."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.tins.2011.11.009","article-title":"Mood-stabilizing drugs: Mechanisms of action","volume":"35","author":"Schloesser","year":"2012","journal-title":"Trends Neurosci."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Iannaccone, T., Sellitto, C., Manzo, V., Colucci, F., Giudice, V., Stefanelli, B., Iuliano, A., Corrivetti, G., and Filippelli, A. (2021). Pharmacogenetics of carbamazepine and valproate: Focus on polymorphisms of drug metabolizing enzymes and transporters. Pharmaceuticals, 14.","DOI":"10.3390\/ph14030204"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40345-020-00215-z","article-title":"Overview of lithium\u2019s use: A nationwide survey","volume":"9","author":"Vieta","year":"2021","journal-title":"Int. J. Bipolar Disord."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11920-015-0603-z","article-title":"Management of Adverse Effects of Mood Stabilizers","volume":"17","author":"Murru","year":"2015","journal-title":"Curr. Psychiatry Rep."},{"key":"ref_26","first-page":"1","article-title":"Mechanism of action of valproic acid and its derivatives","volume":"7","author":"Bourin","year":"2020","journal-title":"SOJ Pharm. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Grunze, A., Amann, B.L., and Grunze, H. (2021). Efficacy of Carbamazepine and Its Derivatives in the Treatment of Bipolar Disorder. Medicina, 57.","DOI":"10.3390\/medicina57050433"},{"key":"ref_28","unstructured":"Chokhawala, K., and Stevens, L. (2022). Antipsychotic Medications, StatPearls Publishing."},{"key":"ref_29","first-page":"341","article-title":"Management of common adverse effects of antipsychotic medications","volume":"17","author":"Stroup","year":"2018","journal-title":"World Psychiatry Off. J. World Psychiatr. Assoc."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/bmb\/ldv017","article-title":"Antipsychotic medication in schizophrenia: A review","volume":"114","author":"Lally","year":"2015","journal-title":"Br. Med. Bull."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/cap.2010.0131","article-title":"Olanzapine use for the adjunctive treatment of adolescents with anorexia nervosa","volume":"21","author":"Norris","year":"2011","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s41983-020-00195-y","article-title":"Olanzapine in the treatment of anorexia nervosa: A systematic review","volume":"56","year":"2020","journal-title":"Egypt. J. Neurol. Psychiatry Neurosurg."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"352865","DOI":"10.1155\/2013\/352865","article-title":"The Pharmacological Options in the Treatment of Eating Disorders","volume":"2013","author":"Milano","year":"2013","journal-title":"ISRN Pharmacol."},{"key":"ref_34","unstructured":"Fariba, K., and Saadabadi, A. (2020). Topiramate, StatPearls Publishing."},{"key":"ref_35","first-page":"1","article-title":"Impulse control disorders: Updated review of clinical characteristics and pharmacological management","volume":"2","author":"Grant","year":"2011","journal-title":"Front. Psychiatry"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1080\/19371918.2013.759031","article-title":"Medications for substance use disorders","volume":"28","author":"Douaihy","year":"2013","journal-title":"Soc. Work Public Health"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"827","DOI":"10.2165\/11591790-000000000-00000","article-title":"Obsessive-compulsive disorder, impulse control disorders and drug addiction","volume":"71","author":"Fontenelle","year":"2011","journal-title":"Drugs"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"14428","DOI":"10.4088\/JCP.19ac13182","article-title":"Pharmacotherapy for treatment-resistant obsessive-compulsive disorder","volume":"81","author":"Kayser","year":"2020","journal-title":"J. Clin. Psychiatry"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000480539","article-title":"Naltrexone in the treatment of broadly defined behavioral addictions: A review and meta-analysis of randomized controlled trials","volume":"23","author":"Mouaffak","year":"2017","journal-title":"Eur. Addict. Res."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Bolton, M., Hodkinson, A., Boda, S., Mould, A., Panagioti, M., Rhodes, S., Riste, L., and van Marwijk, H. (2019). Serious adverse events reported in placebo randomised controlled trials of oral naltrexone: A systematic review and meta-analysis. BMC Med., 17.","DOI":"10.1186\/s12916-018-1242-0"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Tim\u00e4us, C., Meiser, M., Bandelow, B., Engel, K.R., Paschke, A.M., Wiltfang, J., and Wedekind, D. (2019). Pharmacotherapy of borderline personality disorder: What has changed over two decades? A retrospective evaluation of clinical practice. BMC Psychiatry, 19.","DOI":"10.1186\/s12888-019-2377-z"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2217\/fnl-2017-0010","article-title":"Pharmacotherapy of personality disorders: What we know and what we have to search for","volume":"12","author":"Bozzatello","year":"2017","journal-title":"Future Neurol."},{"key":"ref_43","first-page":"121","article-title":"Etiology in psychiatry: Embracing the reality of poly-gene-environmental causation of mental illness","volume":"16","author":"Uher","year":"2017","journal-title":"World Psychiatry Off. J. World Psychiatr. Assoc."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.addbeh.2009.09.003","article-title":"Childhood trauma and health outcomes in adults with comorbid substance abuse and mental health disorders","volume":"35","author":"Wu","year":"2010","journal-title":"Addict. Behav."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"6121","DOI":"10.1038\/s41380-021-01133-x","article-title":"Re-assessing the catecholamine hypothesis of depression: The case of melancholic depression","volume":"26","author":"Gold","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1098\/rstb.2012.0190","article-title":"The neurobiology of depression\u2014Revisiting the serotonin hypothesis. I. Cellular and molecular mechanisms","volume":"367","author":"Albert","year":"2012","journal-title":"Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1177\/2045125314527985","article-title":"Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles","volume":"4","author":"Baumeister","year":"2014","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Malaca, S., Lo Faro, A.F., Tamborra, A., Pichini, S., Busard\u00f2, F.P., and Huestis, M.A. (2020). Toxicology and Analysis of Psychoactive Tryptamines. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21239279"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Lew, S.Y., Lim, S.H., Lim, L.W., and Wong, K.H. (2020). Neuroprotective effects of Hericium erinaceus (Bull.: Fr.) Pers. against high-dose corticosterone-induced oxidative stress in PC-12 cells. BMC Complement. Med. Ther., 20.","DOI":"10.1186\/s12906-020-03132-x"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1515\/REVNEURO.2008.19.6.395","article-title":"Chronic stress-induced hippocampal vulnerability: The glucocorticoid vulnerability hypothesis","volume":"19","author":"Conrad","year":"2008","journal-title":"Rev. Neurosci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3389\/fnhum.2013.00261","article-title":"Relationships among cognition, emotion, and motivation: Implications for intervention and neuroplasticity in psychopathology. Review","volume":"7","author":"Crocker","year":"2013","journal-title":"Front. Hum. Neurosci."},{"key":"ref_52","first-page":"533","article-title":"Serotonin syndrome","volume":"13","author":"Kaye","year":"2013","journal-title":"Ochsner J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.3389\/fpsyt.2021.727117","article-title":"Psychedelics and Other Psychoplastogens for Treating Mental Illness. Review","volume":"12","author":"Vargas","year":"2021","journal-title":"Front. Psychiatry"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.imlet.2020.10.001","article-title":"Psychedelics as a novel approach to treating autoimmune conditions","volume":"228","author":"Thompson","year":"2020","journal-title":"Immunol. Lett."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/PSY.0000000000000161","article-title":"Mood and Anxiety Disorders in Chronic Fatigue Syndrome, Fibromyalgia, and Irritable Bowel Syndrome: Results from the LifeLines Cohort Study","volume":"77","author":"Janssens","year":"2015","journal-title":"Psychosom. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s00393-014-1546-1","article-title":"Fibromyalgiesyndrom","volume":"74","author":"Sommer","year":"2015","journal-title":"Z. Rheumatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s11682-015-9459-4","article-title":"Differential dopamine function in fibromyalgia","volume":"10","author":"Albrecht","year":"2016","journal-title":"Brain Imaging Behav."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2147\/nedt.2006.2.4.537","article-title":"Antidepressants in the treatment of fibromyalgia","volume":"2","author":"Moret","year":"2006","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/07853890.2019.1683601","article-title":"The effect of comorbid medical and psychiatric diagnoses on chronic fatigue syndrome","volume":"51","author":"Natelson","year":"2019","journal-title":"Ann. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2049-9256-2-4","article-title":"The relationship between irritable bowel syndrome and psychiatric disorders: From molecular changes to clinical manifestations","volume":"2","author":"Buga","year":"2014","journal-title":"J. Mol. Psychiatry"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1177\/1099800407307822","article-title":"Relationship of SERT polymorphisms to depressive and anxiety symptoms in irritable bowel syndrome","volume":"9","author":"Jarrett","year":"2007","journal-title":"Biol. Res. Nurs."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.neuroimage.2009.04.083","article-title":"Impact of serotonin transporter gene polymorphism on brain activation by colorectal distention","volume":"47","author":"Fukudo","year":"2009","journal-title":"Neuroimage"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1023\/A:1020994628109","article-title":"Medicinal mushrooms: A rapidly developing area of biotechnology for cancer therapy and other bioactivities","volume":"24","author":"Smith","year":"2002","journal-title":"Biotechnol. Lett."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1353\/pbm.2006.0034","article-title":"Medicinal mushrooms and cancer therapy: Translating a traditional practice into Western medicine","volume":"49","author":"Sullivan","year":"2006","journal-title":"Perspect. Biol. Med."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Murphy, E.J., Rezoagli, E., Major, I., Rowan, N.J., and Laffey, J.G. (2020). \u03b2-glucan metabolic and immunomodulatory properties and potential for clinical application. J. Fungi, 6.","DOI":"10.3390\/jof6040356"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"139330","DOI":"10.1016\/j.scitotenv.2020.139330","article-title":"\u03b2-Glucan extracts from the same edible shiitake mushroom Lentinus edodes produce differential in-vitro immunomodulatory and pulmonary cytoprotective effects\u2014Implications for coronavirus disease (COVID-19) immunotherapies","volume":"732","author":"Murphy","year":"2020","journal-title":"Sci. Total Environ."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"152177","DOI":"10.1016\/j.scitotenv.2021.152177","article-title":"Immunomodulatory activity of \u03b2-glucan polysaccharides isolated from different species of mushroom\u2013A potential treatment for inflammatory lung conditions","volume":"809","author":"Murphy","year":"2022","journal-title":"Sci. Total Environ."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"141362","DOI":"10.1016\/j.scitotenv.2020.141362","article-title":"Unlocking challenges and opportunities presented by COVID-19 pandemic for cross-cutting disruption in agri-food and green deal innovations: Quo Vadis?","volume":"748","author":"Rowan","year":"2020","journal-title":"Sci. Total Environ."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"100254","DOI":"10.1016\/j.coesh.2021.100254","article-title":"Empower Eco multiactor HUB: A triple helix \u2018academia-industry-authority\u2019 approach to creating and sharing potentially disruptive tools for addressing novel and emerging new Green Deal opportunities under a United Nations Sustainable Development Goals framework","volume":"21","author":"Rowan","year":"2021","journal-title":"Curr. Opin. Environ. Sci. Health"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Allam, Z., Sharifi, A., Giurco, D., and Sharpe, S.A. (2021). On the theoretical conceptualisations, knowledge structures and trends of green new deals. Sustainability, 13.","DOI":"10.3390\/su132212529"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/jfbc.12107","article-title":"Wild edible mushrooms as a natural source of phenolics and antioxidants","volume":"39","author":"Yildiz","year":"2015","journal-title":"J. Food Biochem."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"901","DOI":"10.2147\/RMHP.S300656","article-title":"The use of classic hallucinogens\/psychedelics in a therapeutic context: Healthcare policy opportunities and challenges","volume":"14","author":"Bouso","year":"2021","journal-title":"Risk Manag. Healthc. Policy"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2217\/pmt-2017-0068","article-title":"Lysergic acid diethylamide and psilocybin for the management of patients with persistent pain: A potential role?","volume":"8","author":"Whelan","year":"2018","journal-title":"Pain Manag."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1179069518800508","article-title":"Psychoplastogens: A Promising Class of Plasticity-Promoting Neurotherapeutics","volume":"12","author":"Olson","year":"2018","journal-title":"J. Exp. Neurosci."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1080\/14737175.2020.1826931","article-title":"The emerging role of psilocybin and MDMA in the treatment of mental illness","volume":"20","author":"Gill","year":"2020","journal-title":"Expert Rev. Neurother."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12929-020-00688-1","article-title":"The trace aminergic system: A gender-sensitive therapeutic target for IBS?","volume":"27","author":"Pretorius","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.36303\/SAJAA.2020.26.6.S3.2554","article-title":"A review of common psychedelic drugs","volume":"26","author":"Mayet","year":"2020","journal-title":"S. Afr. J. Anaesth. Analg."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1177\/02698811211013583","article-title":"The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects","volume":"36","author":"Uthaug","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"24","DOI":"10.9740\/mhc.2017.01.024","article-title":"Clinical potential of psilocybin as a treatment for mental health conditions","volume":"7","author":"Daniel","year":"2017","journal-title":"Ment. Health Clin."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1755-5949.2008.00059.x","article-title":"The pharmacology of lysergic acid diethylamide: A review","volume":"14","author":"Passie","year":"2008","journal-title":"CNS Neurosci. Ther."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Lowe, H., Toyang, N., Steele, B., Valentine, H., Grant, J., Ali, A., Ngwa, W., and Gordon, L. (2021). The Therapeutic Potential of Psilocybin. Molecules, 26.","DOI":"10.3390\/molecules26102948"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.neuropharm.2011.01.017","article-title":"Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens","volume":"61","author":"Halberstadt","year":"2011","journal-title":"Neuropharmacology"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Cumming, P., Scheidegger, M., Dornbierer, D., Palner, M., Quednow, B.B., and Martin-Soelch, C. (2021). Molecular and functional imaging studies of psychedelic drug action in animals and humans. Molecules, 26.","DOI":"10.3390\/molecules26092451"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1021\/acsptsci.1c00018","article-title":"Naturalistic use of mescaline is associated with self-reported psychiatric improvements and enduring positive life changes","volume":"4","author":"Haas","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/s41386-020-00883-6","article-title":"Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects","volume":"46","author":"Holze","year":"2021","journal-title":"Neuropsychopharmacology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1080\/03602532.2016.1278228","article-title":"Metabolism of psilocybin and psilocin: Clinical and forensic toxicological relevance","volume":"49","year":"2017","journal-title":"Drug Metab. Rev."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1080\/03602532.2019.1638931","article-title":"Metabolism of lysergic acid diethylamide (LSD): An update","volume":"51","year":"2019","journal-title":"Drug Metab. Rev."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2174\/1874467211666181010154139","article-title":"Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions","volume":"12","author":"Pereira","year":"2019","journal-title":"Curr. Mol. Pharmacol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/1355621021000005937","article-title":"The pharmacology of psilocybin","volume":"7","author":"Passie","year":"2002","journal-title":"Addict. Biol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study","volume":"3","author":"Bolstridge","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"943","DOI":"10.3389\/fpsyt.2019.00943","article-title":"Therapeutic use of LSD in psychiatry: A systematic review of randomized-controlled clinical trials","volume":"10","author":"Fuentes","year":"2020","journal-title":"Front. Psychiatry"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/17512433.2018.1415755","article-title":"Novel psychotherapeutics\u2014A cautiously optimistic focus on hallucinogens","volume":"11","author":"Sherwood","year":"2018","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_94","unstructured":"Gopalakrishnakone, P., Carlini, C., and Ligabue-Braun, R. (2017). Plant and fungal hallucinogens as toxic and therapeutic agents. Plant Toxins Toxinology, Springer."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1021\/acsptsci.1c00071","article-title":"The Promise of Psychedelic Science","volume":"4","author":"Olson","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/00952990.2016.1170135","article-title":"Long-term follow-up of psilocybin-facilitated smoking cessation","volume":"43","author":"Johnson","year":"2017","journal-title":"Am. J. Drug Alcohol Abus."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","article-title":"Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder","volume":"67","author":"Moreno","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.3390\/toxins7051431","article-title":"Links between genetic groups, indole alkaloid profiles and ecology within the grass-parasitic Claviceps purpurea species complex","volume":"7","author":"Uhlig","year":"2015","journal-title":"Toxins"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"729425","DOI":"10.3389\/fpsyg.2021.729425","article-title":"Psychedelics, sociality, and human evolution","volume":"12","author":"Winkelman","year":"2021","journal-title":"Front. Psychol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"R156","DOI":"10.1016\/j.cub.2016.12.058","article-title":"Hallucinogenic drugs: A new study answers old questions about LSD","volume":"27","author":"Halberstadt","year":"2017","journal-title":"Curr. Biol."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"De Gregorio, D., Comai, S., Posa, L., and Gobbi, G. (2016). d-Lysergic acid diethylamide (LSD) as a model of psychosis: Mechanism of action and pharmacology. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17111953"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s11481-012-9398-4","article-title":"The molecular basis for neuroimmune receptor signaling","volume":"7","author":"Rogers","year":"2012","journal-title":"J. Neuroimmune Pharmacol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3389\/fpsyt.2019.00672","article-title":"Self-rated effectiveness of microdosing with psychedelics for mental and physical health problems among microdosers","volume":"10","author":"Hutten","year":"2019","journal-title":"Front. Psychiatry"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1177\/0269881120940937","article-title":"A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers","volume":"35","author":"Ramaekers","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1503\/cmaj.141124","article-title":"Psychedelic medicine: A re-emerging therapeutic paradigm","volume":"187","author":"Tupper","year":"2015","journal-title":"Can. Med. Assoc. J."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1021\/acs.jnatprod.1c00264","article-title":"Insights into Ergochromes of the Plant Pathogen Claviceps purpurea","volume":"84","author":"Stroh","year":"2021","journal-title":"J. Nat. Prod."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"905","DOI":"10.3390\/encyclopedia1030069","article-title":"Amanita muscaria: Ecology, Chemistry, Myths","volume":"1","author":"Lopez","year":"2021","journal-title":"Encyclopedia"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1017\/S0953756203007305","article-title":"Amanita muscaria: Chemistry, biology, toxicology, and ethnomycology","volume":"107","author":"Michelot","year":"2003","journal-title":"Mycol. Res."},{"key":"ref_111","first-page":"181","article-title":"Coma in the course of severe poisoning after consumption of red fly agaric (Amanita muscaria)","volume":"63","author":"Pankowska","year":"2016","journal-title":"Acta Biochim. Pol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/BF02246029","article-title":"GABAmimetic agents display anxiolytic-like effects in the social interaction and elevated plus maze procedures","volume":"104","author":"Corbett","year":"1991","journal-title":"Psychopharmacology"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"e01576","DOI":"10.1002\/brb3.1576","article-title":"Simultaneous intrathecal injection of muscimol and endomorphin-1 alleviates neuropathic pain in rat model of spinal cord injury","volume":"10","author":"Hosseini","year":"2020","journal-title":"Brain Behav."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1111\/1556-4029.14368","article-title":"The Psilocin (4-hydroxy-N, N-dimethyltryptamine) and Bufotenine (5-hydroxy-N, N-dimethyltryptamine) Case: Ensuring the Correct Isomer has Been Identified","volume":"65","author":"Kochelski","year":"2020","journal-title":"J. Forensic Sci."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/chem.201904363","article-title":"Simultaneous production of psilocybin and a cocktail of \u03b2--carboline monoamine oxidase inhibitors in \u201cmagic\u201d mushrooms","volume":"26","author":"Blei","year":"2020","journal-title":"Chem.\u2013A Eur. J."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1177\/0269881118769063","article-title":"The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption","volume":"32","author":"Davis","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1080\/21501201003735556","article-title":"Hericenones and erinacines: Stimulators of nerve growth factor (NGF) biosynthesis in Hericium erinaceus","volume":"1","author":"Ma","year":"2010","journal-title":"Mycology"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"111377","DOI":"10.1016\/j.biopha.2021.111377","article-title":"Therapeutic applications of mushrooms and their biomolecules along with a glimpse of in silico approach in neurodegenerative diseases","volume":"137","author":"Rai","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.pbb.2015.06.012","article-title":"Effects of amycenone on serum levels of tumor necrosis factor-\u03b1, interleukin-10, and depression-like behavior in mice after lipopolysaccharide administration","volume":"136","author":"Yao","year":"2015","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"5802634","DOI":"10.1155\/2018\/5802634","article-title":"Neurohealth properties of Hericium erinaceus mycelia enriched with erinacines","volume":"2018","author":"Li","year":"2018","journal-title":"Behav. Neurol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"77","DOI":"10.14480\/JM.2014.12.2.77","article-title":"A comprehensive review of the therapeutic effects of Hericium erinaceus in neurodegenerative disease","volume":"12","author":"Kim","year":"2014","journal-title":"J. Mushroom"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2220\/biomedres.31.231","article-title":"Reduction of depression and anxiety by 4 weeks Hericium erinaceus intake","volume":"31","author":"Nagano","year":"2010","journal-title":"Biomed. Res."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Chiu, C.-H., Chyau, C.-C., Chen, C.-C., Lee, L.-Y., Chen, W.-P., Liu, Y.-L., Lin, W.-H., and Mong, M.-C. (2018). Erinacine A-enriched Hericium erinaceus mycelium produces antidepressant-like effects through modulating BDNF\/PI3K\/Akt\/GSK-3\u03b2 signaling in mice. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19020341"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13020-021-00546-8","article-title":"Neurogenesis-dependent antidepressant-like activity of Hericium erinaceus in an animal model of depression","volume":"16","author":"Chong","year":"2021","journal-title":"Chin. Med."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"101868","DOI":"10.1016\/j.redox.2021.101868","article-title":"Ergothioneine, recent developments","volume":"42","author":"Cheah","year":"2021","journal-title":"Redox Biol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"e00477","DOI":"10.1002\/brb3.477","article-title":"Food-derived hydrophilic antioxidant ergothioneine is distributed to the brain and exerts antidepressant effect in mice","volume":"6","author":"Nakamichi","year":"2016","journal-title":"Brain Behav."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41398-020-0855-1","article-title":"Ergothioneine, a metabolite of the gut bacterium Lactobacillus reuteri, protects against stress-induced sleep disturbances","volume":"10","author":"Matsuda","year":"2020","journal-title":"Transl. Psychiatry"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/s41380-019-0548-4","article-title":"Antidepressant efficacy of a selective organic cation transporter blocker in a mouse model of depression","volume":"25","author":"Coutens","year":"2020","journal-title":"Mol. Psychiatry"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s40262-017-0513-9","article-title":"Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide in healthy subjects","volume":"56","author":"Dolder","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s40262-017-0540-6","article-title":"Pharmacokinetics of escalating doses of oral psilocybin in healthy adults","volume":"56","author":"Brown","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"ref_131","first-page":"405","article-title":"Purified \u03b2-glucans from the Shiitake mushroom ameliorates antibiotic-resistant Klebsiella pneumoniae-induced pulmonary sepsis","volume":"71","author":"Masterson","year":"2020","journal-title":"Lett. Appl. Microbiol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"23079","DOI":"10.1038\/s41598-021-02486-7","article-title":"In vivo toxicity of bioreactor-grown biomass and exopolysaccharides from Malaysian tiger milk mushroom mycelium for potential future health applications","volume":"11","author":"Usuldin","year":"2021","journal-title":"Sci. Rep."}],"container-title":["Journal of Fungi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2309-608X\/8\/3\/290\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:35:02Z","timestamp":1760135702000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2309-608X\/8\/3\/290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,11]]},"references-count":132,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["jof8030290"],"URL":"https:\/\/doi.org\/10.3390\/jof8030290","relation":{},"ISSN":["2309-608X"],"issn-type":[{"value":"2309-608X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,11]]}}}